PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

VaxInnate Corporation

USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, recorded in grant years 2015–2016. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Vaxinnate ranks #30,534 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 5 technology areas.

#30,534
of 49,997 US assignees by volume
36th percentile
by Innovation Score (30.9/100)
33.9
avg claims per patent
-100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30534 · US Corporation #30,534 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #30,534/49,997
  • PHOTO-FINISH Valve Innovations
  • CPC-NARROW C07K · 5 areas
  • INNOV-THIN 30.9/100
  • CLAIMS-DENSE 33.9 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Valve Innovations, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Vaxinnate’s 30.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Vaxinnate

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Vaxinnate's Innovation Score is 30.9/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Vaxinnate?

Each dot is one of Vaxinnate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Vaxinnate’s own 33.9 claims/patent is ABOVE the 15.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Vaxinnate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 010203040 Granted patents (volume) Avg claims / patent Valve Innovations, LLC - 9, 6.44Valve InnovationsVanquish Oncology, Inc. - 9, 12Vanquish OncologyVans, Inc. - 9, 15.44VansVascular Dynamics, Inc. - 9, 14.56Vascular DynamicsVayaVision Sensing Ltd. - 9, 24.89Vayavision SensingVecor IP Holdings Limited - 9, 15.56Vecor IP HoldingsVector Technologies LLC - 9, 29.11VectorVelicept Therapeutics, Inc. - 9, 34.89Velicept Therapeu…VaxInnate Corporation - 9, 33.89Vaxinnate
Vaxinnate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Vaxinnate's grants concentrate

VaxInnate Corporation is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (7 grants) versus a trough of 2 in 2016. By volume, Vaxinnate sits between Valve Innovations, LLC and Velicept Therapeutics, Inc..

Who files at VaxInnate's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows VaxInnate holds 9 patents at rank #30,523, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near VaxInnate

By rank, the assignees closest to #30,523 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in VaxInnate's primary technology class.

Vaxinnate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 20152016 2
USPTO utility patent grants by year · 2015–2016

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
VaxInnate Corporation patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 7 77.8%
2016 2 22.2%

Which technologies does VaxInnate Corporation patent most?

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

VaxInnate Corporation's patent record in context - here's where to go next.

  • VaxInnate Corporation's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #30,534 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare VaxInnate Corporation against Valve Innovations, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 30.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.